恩替卡韋聯(lián)合肝復(fù)樂膠囊治療慢性乙型肝炎肝纖維化80例療效觀察
發(fā)布時間：2019-05-23 10:39
【摘要】：目的探究恩替卡韋(entecavir,ETV)聯(lián)合肝復(fù)樂膠囊治療慢性乙型肝炎肝纖維化的臨床療效。方法選取慢性乙型肝炎肝纖維化患者160例,隨機(jī)分為2組。對照組80例,采用單一ETV治療,聯(lián)合組80例,采用ETV聯(lián)合肝復(fù)樂膠囊治療,療程均為3個月。觀察兩組患者治療前和治療后肝功指標(biāo)、乙型肝炎病毒血清學(xué)標(biāo)志物、HBV DNA載量、肝纖維化指標(biāo)及肝臟影像學(xué)等變化。結(jié)果治療后,聯(lián)合組ALT水平、HBe Ag血清學(xué)轉(zhuǎn)換率、肝纖維化指標(biāo)(HA、LN、PC-Ⅲ、Ⅳ-C)、門靜脈內(nèi)徑及脾臟厚度均顯著低于對照組(P值分別為0.0048、0.0001、0.0019、0.0043、0.0017、0.0002、0.0025和0.0020);HBV DNA低于檢測下限率、AST、TBil、ALB、PT與對照組相比無統(tǒng)計(jì)學(xué)差異(P值分別為1.2922、0.0598、0.0751、0.0972和0.9916)。結(jié)論采用ETV結(jié)合肝復(fù)樂膠囊聯(lián)合治療慢性乙型肝炎肝纖維化臨床效果良好,值得廣泛推廣應(yīng)用。
[Abstract]:Objective to investigate the clinical effect of entecavir (entecavir,ETV) combined with Ganfule capsule in the treatment of chronic hepatitis B liver fibrosis. Methods 160 patients with chronic hepatitis B hepatic fibrosis were randomly divided into two groups. 80 cases in the control group were treated with single ETV and 80 cases in the combined group were treated with ETV combined with Ganfule capsule for 3 months. The changes of liver function index, hepatitis B virus serological marker, HBV DNA load, hepatic fibrosis index and liver imaging were observed before and after treatment. Results after treatment, the serological conversion rate of, HBe Ag at ALT level and the index of hepatic fibrosis (HA,LN,PC- III, IV-C),) in the combined group were compared with those in the control group. The inner diameter of portal vein and the thickness of spleen were significantly lower than those of the control group (P = 0.0048, 0.0001, 0.0019, 0.0043, 0.0017, 0.002, 0.0025 and 0.0020, respectively). HBV DNA was lower than the lower limit rate, and there was no significant difference in AST,TBil,ALB,PT between the control group and the control group (P = 1.2922, 0.0598, 0.0751, 0.0972 and 0.9916, respectively). Conclusion ETV combined with Ganfule capsule is effective in the treatment of chronic hepatitis B liver fibrosis and is worth popularizing and applying widely.
【作者單位】： 呼和浩特市第二(傳染病)醫(yī)院科教科;呼和浩特市第二(傳染病)醫(yī)院檢驗(yàn)科;
【分類號】：R512.62;R575.2
本文編號：2483830
[Abstract]:Objective to investigate the clinical effect of entecavir (entecavir,ETV) combined with Ganfule capsule in the treatment of chronic hepatitis B liver fibrosis. Methods 160 patients with chronic hepatitis B hepatic fibrosis were randomly divided into two groups. 80 cases in the control group were treated with single ETV and 80 cases in the combined group were treated with ETV combined with Ganfule capsule for 3 months. The changes of liver function index, hepatitis B virus serological marker, HBV DNA load, hepatic fibrosis index and liver imaging were observed before and after treatment. Results after treatment, the serological conversion rate of, HBe Ag at ALT level and the index of hepatic fibrosis (HA,LN,PC- III, IV-C),) in the combined group were compared with those in the control group. The inner diameter of portal vein and the thickness of spleen were significantly lower than those of the control group (P = 0.0048, 0.0001, 0.0019, 0.0043, 0.0017, 0.002, 0.0025 and 0.0020, respectively). HBV DNA was lower than the lower limit rate, and there was no significant difference in AST,TBil,ALB,PT between the control group and the control group (P = 1.2922, 0.0598, 0.0751, 0.0972 and 0.9916, respectively). Conclusion ETV combined with Ganfule capsule is effective in the treatment of chronic hepatitis B liver fibrosis and is worth popularizing and applying widely.
【作者單位】： 呼和浩特市第二(傳染病)醫(yī)院科教科;呼和浩特市第二(傳染病)醫(yī)院檢驗(yàn)科;
【分類號】：R512.62;R575.2
【相似文獻(xiàn)】
相關(guān)期刊論文 前1條
1 陳偉麗;聶梅;;肝復(fù)樂膠囊對慢性乙型肝炎患者肝功能及肝纖維化指標(biāo)的影響[J];河南職工醫(yī)學(xué)院學(xué)報;2012年03期
，本文編號：2483830
本文鏈接：http://sikaile.net/yixuelunwen/chuanranbingxuelunwen/2483830.html
最近更新
教材專著
